CANCER

High-accuracy liquid biopsies

Ultra-deep sequencing of paired plasma-circulating free DNA and white blood cells allows the identification of tumor-derived somatic mutations with high accuracy by filtering out variants consistent with clonal hematopoiesis.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Ultra-deep sequencing of paired cfDNA and white blood cells to identify variant origin in a representative cancer patient.

References

  1. 1.

    Razavi, P. et al. Nat. Med. https://doi.org/10.1038/s41591-019-0652-7 (2019).

  2. 2.

    Heitzer, E., Haque, I. S., Roberts, C. E. S. & Speicher, M. R. Nat. Rev. Genet. 20, 71–88 (2019).

    CAS  Article  Google Scholar 

  3. 3.

    Steensma, D. P. et al. Blood 126, 9–16 (2015).

    CAS  Article  Google Scholar 

  4. 4.

    Lui, Y. Y. et al. Clin. Chem. 48, 421–427 (2002).

    CAS  PubMed  Google Scholar 

  5. 5.

    Moss, J. et al. Nat. Commun. 9, 5068 (2018).

    Article  Google Scholar 

  6. 6.

    Snyder, M. W. et al. Cell 164, 57–68 (2016).

    CAS  Article  Google Scholar 

  7. 7.

    Hu, Y. et al. Clin. Cancer Res. 24, 4437–4443 (2018).

    CAS  Article  Google Scholar 

  8. 8.

    Liu, J. et al. Ann. Oncol. 30, 464–470 (2018).

    Article  Google Scholar 

  9. 9.

    Takahashi, K. et al. Lancet Oncol. 18, 100–111 (2017).

    Article  Google Scholar 

  10. 10.

    Gillis, N. K. et al. Lancet Oncol. 18, 112–121 (2017).

    Article  Google Scholar 

  11. 11.

    Jaiswal, S. et al. N. Engl. J. Med. 377, 111–121 (2017).

    Article  Google Scholar 

  12. 12.

    Bolton, K. L. et al. J. Clin. Oncol. 37, 7–11 (2019).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Beatriz Bellosillo.

Ethics declarations

Competing interests

B.B. has received honoraria for a speaker, consultancy or advisory role from Astra-Zeneca, Biocartis, Merck Serono, Novartis, Qiagen, Hoffman–La Roche, ThermoFisher, Pfizer and Bristol-Myers Squibb. C.M. declares institutional research funding from Amgen, Bayer, Biocartis, BMS, Merck Serono, Roche, and Sanofi Aventis as well as advisory board or speaker fees from Amgen, Biocartis, Merck Serono, Roche, Symphogen, Guardant Health, Seattle Genetics and Sysmex.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bellosillo, B., Montagut, C. High-accuracy liquid biopsies. Nat Med 25, 1820–1821 (2019). https://doi.org/10.1038/s41591-019-0690-1

Download citation